Soon after rapamycin, the first mTOR inhibitor, emerged in 1990s as a potential treatment against unwanted cell proliferation, many cancer experts had hoped emerging drugs targeting mTOR would ...

One postulation is that some mTORC2 components may block the binding of rapamycin/FKBP12 complex to the FRB domain of mTOR. Under this assumption, prolonged rapamycin treatment may decrease mTORC2 ...

As discussed below, good scientific reasons are emerging as to why rapamycin might benefit particular tumour types, and the hope is that with the proper insights this drug or other mTOR inhibitors ...

The results suggested that mechanistic target of rapamycin (mTOR) inhibition is a potential therapeutic avenue for sarcoidosis, which the authors said should be explored in larger clinical trials.

Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging ...

Therefore, it is necessary to identify druggable pathways and develop new therapeutic strategies against them. The PI3K-Akt-mTOR pathway regulates several biological functions and it is frequently ...

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of ...

What is the most troublesome side effect of mTOR inhibitors? In my opinion, pneumonitis is the most troublesome side effect as it can be medically very dangerous if not identified and treated early.